NCT00876109View on ClinicalTrials.gov

A Study of GDC-0941 in Participants With Locally Advanced or Metastatic Solid Tumors for Which Standard Therapy Either Does Not Exist or Has Proven Ineffective or Intolerable

PHASE1CompletedINTERVENTIONAL

Enrollment

108

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

June 30, 2012

Study Completion Date

November 30, 2013

Conditions

Solid Cancers

Interventions

DRUG

GDC-0941

GDC-0941 will be administered in escalating oral doses QD or BID in Groups A and B, respectively. In Group C, the dose/regimen will be determined on the basis of data from Groups A and B. The overall starting dose will be 15 mg administered in the first cohort enrolled in Group A.

Trial Locations (3)

48201

Detroit

85258

Scottsdale

02215

Boston